Skip to content

Irinotecan EP Impurity L

Irinotecan EP Impurity L

Product Description
CAT No.
ALN-I010035
CAS No.
1255644-71-3
Mol. F.
C33H38N4O6
Mol. Wt.
586.7
Stock
Please Inquire
RFQ
Chemical Name : (4R)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-9-yl 1,4′-bipiperidine-1′-carboxylate (as per EP)
Smiles : O=C(N1CCC(N2CCCCC2)CC1)OC3=CC=C4N=C5C(CN6C(C(COC([C@]7(CC)O)=O)=C7C=C65)=O)=C(CC)C4=C3
Inchi : InChI=1S/C33H38N4O6/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3/t33-/m0/s1
Synonym : Irinotecan USP Related compound D ; Irinotecan Enantiomer (EP)

RP-HPLC method development and validation for the simultaneous estimation of Irinotecan hydrochloride and Capecitabine in Active Pharmaceutical Ingredients (APIs)

By Vijaya Jyothi, M.; Bhargav, E.; Keerthana, B.; Varalakshmi, Devi K.nFrom International Journal of Research in Pharmaceutical Sciences (Madurai, India) (2018), 9(1), 63-67

Method development, validation and forced degradation studies of Irinotecan in bulk and pharmaceutical dosage form

By Swathi, Koduru; Farooqui, Tahmeena; Muntaha, Sidra Tul; Ayesha, Syeda Amtul; Shama, Syeda; Siddiqui, Sarah Imam – From World Journal of Pharmacy and Pharmaceutical Sciences (2018), 7(8), 996-1009

Request For Quotation

Related Products